Idaho Clinical Trials Report — May 2026

For Idaho residents considering participation in clinical research, May 2026 presents a crucial window of opportunity, particularly for those looking to join studies that are nearing their enrollment deadlines. Across the state, 18 clinical trials are slated to close within the next 90 days. This urgency extends to healthy volunteers, with 1 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on specific types of cancer, fungal infections, and chronic conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Stage IV lung cancer AJCC V8
• Vulvovaginal candidiasis (VVC)
• Anatomic stage III breast cancer AJCC V8
• Atopic dermatitis
• Chronic granulomatous disease (CGD)
• COPD
• Hormone receptor-positive breast carcinoma
• HER2-negative breast carcinoma
• Idiopathic short stature
• Major depressive disorder

Major Research Initiatives Launch in Idaho

This month brings several high-profile new trials to Idaho, including significant Phase 3 studies from a major pharmaceutical company. These trials offer participants the chance to engage with cutting-edge treatments addressing prevalent health challenges like obesity and heart failure.

• Novo Nordisk A/S is sponsoring NCT07567001, a Phase 3 study titled "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This substantial trial aims to enroll 5,610 participants globally, evaluating the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight.
• Another significant Phase 3 study from Novo Nordisk A/S is NCT07564414, "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This trial seeks to enroll 2,500 participants to assess the safety and effectiveness of CagriSema for body weight loss in people with obesity, with or without type 2 diabetes. The purpose of this study is to find out how safe and effective CagriSema is for body weight loss in these participants.

Idaho's Evolving Research Landscape

This month, Idaho saw the opening of 2 new clinical trials, maintaining the same pace as April 2026 and March 2026, which also saw 2 new trials each. While the number of new openings is consistent, the state continues to offer a broad array of research opportunities, with a total of 331 clinical trials currently recruiting across 24 cities and 188 research sites statewide.

The new research initiatives this month are concentrated in a single location, with both new trials opening in Meridian. This indicates a focused effort in one of Idaho's growing metropolitan areas. New studies are exploring a range of conditions, from common ailments to more specialized areas. This month's new trials are targeting:

• Obesity
• Heart failure
• Type 2 diabetes

Both new studies are drug trials, reflecting an industry-driven focus on pharmaceutical advancements. Notably, both new trials are sponsored by Novo Nordisk A/S, a major industry player in metabolic and cardiovascular health research.

Participation Opportunities: Healthy Volunteers and Demographics

Participation in clinical trials is open to a wide range of individuals. Of the 2 new trials launched this month, both include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. No new trials this month are specifically for children, or female-only or male-only participants.

For individuals without a specific medical condition, there are ongoing opportunities to contribute. While neither of the new trials this month are actively seeking healthy volunteers, there are still 23 clinical trials currently recruiting healthy participants across Idaho. These studies provide numerous avenues for those interested in supporting medical research without having a specific health condition.

As we move through May, the focus will likely remain on the ongoing enrollment in these significant Phase 3 trials, while researchers prepare for the next wave of innovative studies to address a broad spectrum of health challenges across Idaho. Residents are encouraged to explore the diverse opportunities available and consider how their participation can advance medical knowledge.